Loading...
Loading...
Browse all stories on DeepNewz
VisitLegal action against Alcon over Systane recall by end of 2025?
Yes • 50%
No • 50%
Court records or official news reports
Alcon Recalls Systane Lubricant Eye Drops Ultra PF, Lot 10101, Nationwide Due to Fungal Contamination
Dec 24, 2024, 05:31 PM
Alcon Laboratories, based in Fort Worth, Texas, has issued a voluntary recall of a single lot of Systane Lubricant Eye Drops Ultra PF due to potential fungal contamination. The affected product, sold in 25 single-use 'on-the-go' vials, was distributed nationwide to retail and online outlets including Walgreens, CVS, and Target. The recalled lot, identified by lot number 10101 and an expiration date of September 2025, was recalled after a consumer reported finding foreign material in a sealed vial, which was later confirmed to be fungal. The FDA warns that fungal contamination in eye products can lead to serious eye infections, potentially causing partial vision loss, blindness, or in rare cases, life-threatening conditions for immunocompromised individuals. No adverse events related to this recall have been reported to date. Consumers are advised to stop using the recalled eye drops immediately and return them to the place of purchase for a replacement or refund.
View original story
Increase by more than 10% • 25%
Other outcome • 25%
Decrease by more than 10% • 25%
No significant change (+/- 10%) • 25%
Fine imposed • 25%
No further action • 25%
Mandatory product reformulation • 25%
Temporary production halt • 25%
Decreased trust in Alcon • 25%
No significant change • 25%
Increased demand for safer packaging • 25%
Switch to alternative brands • 25%
No specific cause identified • 25%
Manufacturing defect • 25%
Supply chain contamination • 25%
Other cause • 25%
Alcon gains market share • 25%
Other outcome • 25%
Alcon loses market share • 25%
No significant change • 25%
Europe • 25%
North America • 25%
Other regions • 25%
Asia • 25%
Increased quality checks • 25%
Product reformulation • 25%
Discontinue product • 25%
No significant changes • 25%
Major compliance issues • 25%
Recall expanded • 25%
Minor compliance issues • 25%
No issues found • 25%